The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.
Neurokin’s founders have shown that proprietary CDK inhibitors that are antimitotic are also active against non-mitotic specific neuronal CDK. The specific activities of our small drug-like molecules give them an anti-apoptotic and anti-excitotoxic properties for neurons and an anti inflammatory properties for glial cells. NK molecules are attractive neuroprotectants because they are multi-targets (neurons, glial cells) as well as multi-pathways active agents.
Proof of concept with a compatible human administration route has been shown in different in vivo models including stroke (permanent and transient), epilepsy and traumatic brain injury pre and post-treatment. In the tMCAO model in rat, NK-102 is able to decrease the total volume of infarction of 30% and the volume of cortical infarction of 50% at least 2 hours after the beginning of ischemia.
NK candidates cross blood brain barriers. No toxicity has been observed in different models in vitro and in vivo. Neurokin has developed its lead candidate NK-102 up to the start of the regulatory preclinical studies and develops NK-2210 from another chemical family which is a 10 fold more potent CDK inhibitor.
Neurokin has worldwide exclusive licenses for NKs, and has filed a specific patent for its lead candidate NK-102.
